FDA yemeje ibrutinib mu kuvura indwara idakira ya graft-versus-host (cGVHD) ku bana

Ku ya 24 Kanama 2022, Ikigo gishinzwe Ibiribwa n'Imiti muri Amerika (FDA) cyemeje ibrutinib mu kuvura abana barengeje umwaka umwe bafite indwara idakira yo kwangirika (cGVHD) bahabwa nyuma yo kunanirwa kwa 1- cyangwa multi-line therapy. Ikimenyetso cyemewe ni icy'abarwayi b'abana, aho igipimo rusange cy'ubutabazi ari 60% mu cyumweru cya 25, kandi imiti irimo capsules, ibinini n'imiti yo kunywa.

Ibrutinib, umuti ugabanya ubukana bwa BTK wakozwe na Pharmacyclics/Johnson & Johnson, ni umuti ugabanya ubukana bwa kinase wari wemejwe mbere mu kuvura kanseri y’amaraso ifata imitsi (leukemia) ndetse na kanseri y’uturemangingo n’izindi ndwara.

Suntech yibanda ku iterambere n'ikorwa ry'imiti ikoreshwa mu buvuzi bw'icyatsi kibisi na APIs hakoreshejwe ikoranabuhanga ritangiza ibidukikije. Kuri ubu, ikigo cyacu cyakoze ibicuruzwa bitatu bikoreshwa mu buvuzi bw'icyatsi kibisi birimo C AS: 143900-44-1, C AS: 330792-70-6, C AS: 330786-24-8, byose byagurishijwe mu nganda zikora GMP. Muri byo, hagati ya C AS: 143900-44-1 ikorwa hakoreshejwe ikoranabuhanga rya chimique-enzymatic, rifite ibyiza byo kurengera ibidukikije, igiciro gito n'ubwiza bwo hejuru. Murakaza neza kugira ngo mugire inama kandi mufatanye!